Publication date: Jan 19, 2025
Objectives: To compare the outcomes of tracheostomised COVID-19 patients with non-COVID-19 tracheostomised patients to identify factors influencing severity and mortality. Methods: A retrospective, single-centre cohort study was conducted on COVID-19 tracheostomised patients admitted from May 2020 to February 2022, compared with a cohort of non-COVID-19 tracheostomised patients. Results: COVID-19 tracheostomised patients had a higher mortality rate (50% vs. 27. 3% in non-COVID-19 patients). Mortality risk factors in COVID-19 tracheostomised patients included female sex (HR 1. 99, CI 1. 09-3. 61, p = 0. 025), ischemic heart disease (HR 5. 71, CI 1. 59-20. 53, p = 0. 008), elevated pre-tracheostomy values of PEEP (HR 1. 06, CI 1. 01-1. 11, p = 0. 017) and INR (HR 1. 04, CI 1. 01-1. 07, p = 0. 004), and ventilatory complications (HR 8. 63, CI 1. 09-68. 26, p = 0. 041). No significant differences in complication rates were found based on Sars-CoV-2 infection or tracheostomy type. Conclusions: Tracheostomy technique did not impact complications, discharge circumstances, or mortality, supporting the safety of bedside percutaneous tracheostomies for COVID-19 patients. COVID-19 tracheostomised patients exhibited a higher mortality rate.
Open Access PDF
| Concepts | Keywords |
|---|---|
| February | airway obstruction |
| Sex | epidemiology |
| Tracheostomy | infectious diseases |
| pandemics | |
| trachea |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | Complications |
| disease | MESH | ischemic heart disease |
| pathway | REACTOME | SARS-CoV-2 Infection |
| drug | DRUGBANK | Coenzyme M |
| drug | DRUGBANK | Filgrastim |
| disease | MESH | infectious diseases |
| disease | MESH | airway obstruction |
| disease | MESH | acute respiratory distress syndrome |
| disease | MESH | hypoxemia |
| disease | MESH | weaning |
| disease | IDO | process |
| disease | MESH | bleeding |
| disease | MESH | pneumothorax |
| disease | MESH | obesity |
| disease | IDO | history |
| disease | MESH | respiratory failure |
| disease | MESH | sepsis |
| disease | IDO | symptom |
| disease | MESH | dyspnea |
| disease | IDO | site |
| disease | MESH | subcutaneous emphysema |
| disease | MESH | stenosis |
| disease | MESH | death |
| drug | DRUGBANK | Gold |
| disease | MESH | infection |
| disease | MESH | heart failure |
| drug | DRUGBANK | Heparin |
| disease | MESH | contraindication |
| disease | MESH | Influenza |
| disease | MESH | hypertension |
| disease | MESH | COPD |
| disease | MESH | hypercholesterolemia |
| disease | MESH | causes |
| disease | MESH | tics |
| disease | MESH | postoperative complications |
| pathway | REACTOME | Metabolism |
| disease | MESH | comorbidity |